News

In an introduction to our April publication, explore an overview of topics covered in this issue and an introduction to our Spring Editor in Chief, Aaron Farberg, MD.

Data was recently published in the International Wound Journal supporting positive outcomes in moderate or severe ulcers.

Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including the launch of an expanded job board for dermatology support roles, CMS and Incyte's collaboration for povorcitinib in China and Southeast Asia, and more.

ICYMI, this week we had news about Ycanth's J-code launch, highlights from Diversity in Dermatology, bimekizumab's accepted sBLA for HS, and more.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

In a comparative study, benzyl benzoate demonstrated superior efficacy in scabies cases, while topical permethrin exhibited a lack of effectiveness.

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

Researchers address the persisting gaps in managing mental health comorbidities within the framework of existing clinical practice guidelines.

Influencers promote the use of tanning beds and list the “benefits,” such as obtaining vitamin D and helping with seasonal affective disorder, among other reasons that have no merit.

This week’s collection of the latest dermatologic studies covers topical permethrin 5% vs. benzyl benzoate 25% for scabies, the safety of omalizumab in CSU during pregnancy, symptoms of cognitive impairment in children with AD, and the ethics of cosmetic overtreatment.

In a literature review, researchers found data supporting the efficacy and safety of fillers in patients with skin of color, particularly for populations where is there is limited data.

Versus placebo, topical melatonin and rosuvastatin reduced psoriatic plaque severity with a favorable safety profile.

The submission stems from promising results from the phase 3 BE HEARD I and BE HEARD II trials.

The risk of upper respiratory infection-related mortality was notably diminished in the study's dupilumab cohort.

One study uncovered high levels of CGRP in patients with rosacea, with levels not affected by age, sex, BMI, and other factors.

In this study, topical 0.1% retinol significantly improved crow’s feet, facial wrinkles, uneven skin tone, brown spots, and overall photoaging.

In this week’s Pointers With Portela, the 208SkinDoc reviews how the skin is affected during hormonal changes and menopause.

The new launch is set to bring berdazimer topical gel, 10.3% to adults and pediatric patients over the age of 1 with molluscum contagiosum faster.

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.

The agreement for a second confirmatory trial comes after a successful phase 3 FLASH study that yielded positive outcomes and efficacy.

While the addition of NAC yielded greater improvement than microneedling alone, this difference was not significant.

Shah discusses the science behind his products, as well as the challenges he didn’t anticipate when launching Remedy.

The biosimilar landscape experienced significant activity, marked by fresh data from conferences, novel findings regarding adalimumab biosimilars, and more.

Shahriari shares pearls and considerations from her sessions at the recent Diversity in Dermatology conference.

A recent study aimed to investigate the risk of myocardial infarction, cerebrovascular accident, peripheral vascular disease, and pulmonary embolism in patients with vitiligo.

Over 50% of women in their 20s and over 35% of women aged 30 to 39 years struggle with adult female cystic acne.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.